ABSTRACT
This chapter describes trade name, classification, approved indications for psychological disorders, available dosage forms, storage, and compatibility, usual dosage and administration, relative contraindications, and clinically significant drug interactions of Alprazolam. The goal of alprazolam pharmacotherapy for the symptomatic management of panic disorder is a substantial reduction in panic attacks or their total elimination. Early morning anxiety and the emergence of signs and symptoms of anxiety between doses have been reported among patients receiving alprazolam pharmacotherapy at recommended maintenance dosages. Once the control of panic attacks has been achieved, discontinue alprazolam pharmacotherapy gradually. Seizures also have been associated with the discontinuation of alprazolam pharmacotherapy or upon abrupt reduction of dosage. Immediate management of the signs and symptoms of withdrawal may require reinstitution of alprazolam pharmacotherapy at a dosage sufficient to relieve the signs and symptoms of withdrawal.
